Banca de QUALIFICAÇÃO: TEREZINHA CARLA CARVALHO DA SILVA

Uma banca de QUALIFICAÇÃO de DOUTORADO foi cadastrada pelo programa.
STUDENT : TEREZINHA CARLA CARVALHO DA SILVA
DATE: 25/09/2024
TIME: 14:00
LOCAL: Google meeting - on-line
TITLE:

Experimental neuroprotective and neuroregenerative treatment protocol with cannabidiol nanoemulsion in association with delta-9-tetrahydrocannabinol for Alzheimer's disease in Wistar rats subjected to an induction model with scopolamine hydrobromide.

KEY WORDS:

Cannabinoids; Endocannabinoids; Phytocannabinoids; Dementia.

PAGES: 150
BIG AREA: Ciências Agrárias
AREA: Medicina Veterinária
SUBÁREA: Patologia Animal
SPECIALTY: Anatomia Patologia Animal
SUMMARY:

Alzheimer's disease (AD) affects more than 50 million people worldwide. Available pharmacological treatments do not interrupt the degenerative process and do not have neuroprotective effects. Given this pharmacotherapeutic difficulty, studies with cannabinoids are being developed with the aim of improving the understanding of the action of Cannabis sp on the central nervous system. The aim of this research was to analyze and evaluate the neuroprotective and neuroregenerative therapeutic effects of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (Δ9-THC) through behavioral tests, laboratory tests, and histopathological and morphometric studies. For this purpose, 48 male Wistar rats, 90 days old, were used, kept under a 12-hour light/dark cycle, at a temperature of 20-24°C, and divided into six experimental groups (n=8). Inductions and treatments occurred at the age of 270 days. With the exception of Group I, the other groups were experimentally induced to AD with scopolamine hydrobromide intraperitoneally at doses of 3 mg/kg every 24 h for 7 consecutive days. Group I (negative control) animals were not induced or treated; Group II (positive control for CBD/Δ9-THC) individuals not induced but treated with CBD and Δ9-THC (1:3); Group III - animals in this group were induced to AD with scopolamine hydrobromide intraperitoneally every 24 h for 7 days, but were not treated; Group IV - rats were induced to AD for 7 days and on the 8th day began treatment with corn oil nanoemulsion rectally for 15 days; Group V animals received induction with scopolamine hydrobromide for 7 days intraperitoneally and from the eighth day onwards they were treated with CBD+ Δ9-THC 1:3 (rectally) for 15 days; Group VI – Animals treated early with CBD and Δ9-THC 1:3 for 15 days rectally every 24 h and on the 16th day the rats began to receive induction with scopolamine hydrobromide 3mg/g every 24 h intraperitoneally for 7 consecutive days. The project developed an experimental therapeutic protocol with a nanotechnological suppository formulation of CBD and Δ9-THC nanoemulsion for the treatment of Alzheimer's disease.

COMMITTEE MEMBERS:
Interno - JOSE VITOR MOREIRA LIMA FILHO
Interno - PABYTON GONCALVES CADENA
Interna - TANIA MARIA SARMENTO DA SILVA
Interno - VALDEMIRO AMARO DA SILVA JUNIOR